Katherine G Tarlock
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium · COG Phase I Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Katherine G Tarlock as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06609928 · FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid LeukemiaFred Hutchinson Cancer Center · recruiting · Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia · principal investigator
- Ph1NCT03813147 · Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNational Cancer Institute (NCI) · completed · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.